Neurology Alert – August 1, 2022
August 1, 2022
View Archives Issues
This meta-analysis provides evidence that drugs modulating the noradrenergic system could be effective in treating cognitive symptoms and apathy in patients with Alzheimer’s disease.
Two independent analyses of U.S. national surveys support evidence that targeted risk-reduction strategies may reduce the burden of Alzheimer’s disease in the population.
Prolonged fatigue after COVID-19 infection may be associated with evidence of myopathy, based on physical examination, electromyography, and muscle biopsy.
Headache is a common feature of acute COVID-19 infection, as well as a long-standing feature of “long COVID” after recovery from the acute infection. Treatment is symptomatic, based on the characteristics of the headache syndrome.